A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (NCT04232553)

🧪 Interventions in This Study

• Mirikizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (322 Sites)

Showing the first 25 of 322 sites.

• Digestive Health Specialists — Dothan, Alabama
• Research Solutions of Arizona — Litchfield Park, Arizona
• Arizona Arthritis & Rheumatology Research, PLLC — Phoenix, Arizona
• Care Access - Gilroy — Gilroy, California
• Newport Huntington Medical Group — Huntington Beach, California
• California Medical Research Associates — Northridge, California
• Connecticut Clinical Research Institute — Bristol, Connecticut
• Gastroenterology Consultants of Clearwater — Clearwater, Florida
• Clinical Research of West Florida, Inc. (Clearwater) — Clearwater, Florida
• IHS Health Research — Kissimmee, Florida
• Ezy Medical Research — Miami, Florida
• Care Access - Orlando — Orlando, Florida
• Gastroenterology Associates of Pensacola, PA — Pensacola, Florida
• Precision Clinical Research — Sunrise, Florida
• USF Health — Tampa, Florida
• Alliance Clinical Research of Tampa — Tampa, Florida
• Digestive Healthcare of Georgia — Atlanta, Georgia
• Gastrointestinal Specialists of Georgia — Marietta, Georgia
• Grand Teton Research Group — Idaho Falls, Idaho
• Qualmedica Research, LLC — Evansville, Indiana
• Indiana University Health University Hospital — Indianapolis, Indiana
• Delta Research Partners — Monroe, Louisiana
• Capital Digestive Care - Chevy Chase — Chevy Chase, Maryland
• Woodholme Gastroenterology Associates - Glen Burnie — Glen Burnie, Maryland
• The Digestive Health Center of Michigan (DHCMI) — Chesterfield, Michigan

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn's Disease

• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
• Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
• Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts

Explore by condition: All Crohn's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.